PUBLISHER: DelveInsight | PRODUCT CODE: 1462261
PUBLISHER: DelveInsight | PRODUCT CODE: 1462261
"LSTA-12 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about LSTA-12 for Peripheral Artery Disease (PAD) in Japan. A detailed picture of the LSTA-12 for PAD in Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LSTA-12 for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LSTA-12 market forecast analysis for PAD in Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.
LSTA-12 (also known as Honedra and CLBS12 in Japan) is an experimental regenerative medicine to prevent the serious adverse consequences of CLI and Buerger's disease by improving blood flow in the affected limb. It is CD34+ cell therapy intended to administer by Intramuscular route, 20 injections in the target limb in a single treatment.
The CD34+ cell was discovered due to the deliberate search for a stem cell capable of stimulating blood vessels' development and/or repair. All tissues in the human body maintain their function by replacing cells over time. By administering CD34+ cells, the company promotes the development and formation of new microvasculature, thereby increasing blood flow to the impacted area. No other native cell discovered to date has demonstrated this same capability.
The initial clinical responses are consistent with a positive therapeutic effect and safety profile and with previously published clinical trials of CD34+ cell therapy in Japan and elsewhere.
Caladrius' proprietary CD34+ cell therapy technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Caladrius believes that several conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology, including but not limited to coronary microvascular dysfunction (CMD), critical limb ischemia (CLI), diabetic kidney disease (DKD), and no-option refractory disabling angina (NORDA).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
LSTA-12 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of LSTA-12 for Peripheral Artery Disease (PAD) in Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of LSTA-12 for PAD covering trial interventions, trial conditions, trial status, start and completion dates.